SCHEMBL6147447

SCHEMBL6147447

CCCCCC(COc1ccc(C(=O)O)cc1)c1ccc2c(c1)C(C)(C)CCN2CC

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RARB P10826 2/20 0.54
RARG P13631 2/20 0.54
CYP26A1 O43174 2/20 0.54
CYP3A4 P08684 2/20 0.54
CYP26B1 Q9NR63 2/20 0.54
RXRA P19793 5/20 0.45
HNF4A P41235 1/20 0.45
PLA2G4B P0C869 2/20 0.42
PPARG P37231 5/20 0.41
PPARA Q07869 5/20 0.41
RARA P10276 1/20 0.41
RXRB P28702 1/20 0.41
TP53 P04637 1/20 0.40
TSHR P16473 1/20 0.40
PTGER4 P35408 1/20 0.40
PTGER2 P43116 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4848993 0.93 CYP26A1 (0.54) RARBRARGCYP26A1CYP3A4CYP26B1
SCHEMBL6144443 0.91 RARB (0.45) RARBRARGCYP26A1CYP3A4CYP26B1
SCHEMBL6146459 0.87 CYP26A1 (0.71) RARBRARGCYP26A1CYP3A4CYP26B1
SCHEMBL6144103 0.87 CYP26A1 (0.71) RARBRARGCYP26A1CYP3A4CYP26B1
SCHEMBL6144279 0.87 CYP26A1 (0.71) RARBRARGCYP26A1CYP3A4CYP26B1
SCHEMBL4844416 0.86 CYP26A1 (0.54) RARBRARGCYP26A1CYP3A4CYP26B1
SCHEMBL6144560 0.81 CYP3A4 (0.55) RARBRARGCYP26A1CYP3A4CYP26B1
SCHEMBL6151767 0.80 CYP26A1 (0.53) RARBRARGCYP26A1CYP3A4CYP26B1
SCHEMBL6147333 0.80 RARB (0.44) RARBRARGRXRAHNF4APPARG
SCHEMBL6147329 0.80 RARB (0.44) RARBRARGRXRAHNF4APPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1280757-B1 NEW GAMMA SELECTIVE RETINOIDS HOFFMANN LA ROCHE (CH) 2005-08-17 EP claimed
EP-1280757-A2 NEW GAMMA SELECTIVE RETINOIDS F. HOFFMANN-LA ROCHE AG (CH) 2003-02-05 EP claimed
US-20020026060-A1 RAR selective retinoid agonists F.HOFFMANN-LA ROCHE AG (CH) 2002-02-28 US claimed
WO-2001083438-A2 NEW GAMMA SELECTIVE RETINOIDS F. HOFFMANN-LA ROCHE AG (CH) 2001-11-08 WO claimed
EP-1280757-B1 NEW GAMMA SELECTIVE RETINOIDS HOFFMANN LA ROCHE (CH) 2005-08-17 EP disclosed
US-6603012-B2 RAR selective retinoid agonists HOFFMANN-LA ROCHE INC. 2003-08-05 US disclosed
US-20020026060-A1 RAR selective retinoid agonists F.HOFFMANN-LA ROCHE AG (CH) 2002-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020026060-A1 RAR selective retinoid agonists RARA, RARG, RARB RARB 3/4885RARG 2/4885CYP26A1 474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.